3 min read
If you are planning Pharmaceutical Market Entry in Singapore in 2026, you must prepare for several critical regulatory, efficiency, compliance and operational reforms instituted by the Health Sciences Authority (HSA) in 2025. These developments set new expectations in product registration, dossier preparation, electronic reporting, GMP, and life-cycle compliance (post-market safety tracking) under evolving Singapore pharmaceutical regulations.
Understanding these Regulatory updates is essential for companies seeking smooth Pharmaceutical Market Entry in Singapore and long-term compliance success.
1. Revised Dossier and Technical Documentation Requirements (2025)
- Singapore fully aligns submission requirements for new chemical and biological therapeutics with the ASEAN Common Technical Dossier (ACTD) and ICH Common Technical Document (CTD), emphasizing structured, detailed technical dossiers for both initial registration and variation applications.
- Key updates include evidence and standards for Good Manufacturing Practice (GMP), dossier composition, and eligibility requirements for specific regulatory pathways (e.g., standard, verification, biosimilar, and essential medicine submission types).
- The HSA has implemented formal GMP inspection routes for overseas manufacturers, new submission pathway for standard and essential medicines through the generic drugs applications, flexibility in the restrictions for submission of variation applications through the PRISM portal and stricter guidance on post-marketing vigilance for therapeutic products.
- For major and minor variations, new detailed checklists and guidance for chemical and biological products have been published (Appendices 13A, 13B, 14A, and 14B), clarifying tabulated comparative batch data, stability studies, process validation, and commitment letters about ongoing studies. These changes significantly impact ACTD submission Singapore requirements for pharmaceutical companies.
Full ACTD submission guide: ASEAN CTD Checklist MAV Guidance
2. Electronic Application Systems and Digitalization
- All pharmaceutical product registrations, post-approval changes, and dealer licensing must be performed through HSA’s PRISM and SHARE electronic submission systems.
- Launch of SHARE portal as the exclusive platform for advanced therapy and cell/gene therapy dealer licensing (as of February 2025), replacing legacy submission methods and strengthens digital compliance expectations under HSA Singapore regulations.
- The enhanced use of the HSA PRISM portal also improves Regulatory tracking, submission efficiency, and lifecycle management for applicants pursuing Pharmaceutical Market Entry in Singapore.
- The upgrade in digital infrastructure by introduction of the SHARE System has mandated manufacturers to develop new internal compliance and detailed regulatory submission processes, applicable to both Singapore-based and international applicants.
All stakeholders / applicants can use the SHARE portal for submissions and adopting workflows requirements like presenting digital declarations, amending processes, and uploading documents.
SHARE FAQ: HSA SHARE for CTGTP
3. Advanced Therapy Product Registration (2025 Update)
- New comprehensive guidance for registration and variations for cell, tissue, and gene therapy products (CTGTPs), including application routes, GMP assessment, RMP, Environmental Risk Assessment, and e-payment processes.
- Digital workflow submission is now mandatory for all CTGTP registration Singapore activities, including licensing and post-approval variations.
- Access to sponsors without CRIS account for the SHARE system applications, clear pre-market entry consultation by HSA, establishment of a pre-registered inter-bank payment channel named GIRO for auto - payment of submission and renewal fees, stringency on data requirements for clinical data in the dossier, harmonizing with globally recognized standards by stringent regulatory authorities and transparency in the registration process for the applicant are some of the measures implemented.
Guidance: CTGTP Guidance Singapore
4. Strengthened Product Defect Reporting and Recall Procedures
- All licensees are required to have robust systems for product defect reporting, investigation, and recall—with written SOPs, staff training, and electronic readiness for prompt communication with HSA.
- New consolidated guidance (for defect reporting, recall, recordkeeping, distribution chain management, risk assessment / CAPA, regulatory implications due to non-compliance), establishing official digital platform for reporting of product defects, defining timelines for submission of such evidence to HSA, inclusion of each stakeholder to legally share responsibility in case of recall / reporting as some of the measures the HSA has implemented in recent updates.
- These strengthened recall and reporting obligations further reinforce compliance standards for companies planning Pharmaceutical Market Entry in Singapore.
Reference: Product Defect & Recall Workshop
Conclusion
The evolving Regulatory landscape in Singapore reflects HSA’s continued focus on digitalization, advanced therapies, lifecycle compliance, and stronger quality oversight. Companies preparing for Pharmaceutical Market Entry in Singapore must proactively align with updated dossier requirements, electronic submission systems, and post-market compliance obligations to ensure efficient Regulatory approval and sustained market access.
Freyr supports pharmaceutical and life sciences companies with end-to-end Regulatory services in Singapore, including ACTD dossier preparation, HSA submissions, lifecycle management, CTGTP Regulatory support, labeling, and post-approval compliance assistance.
To learn more about how Freyr can support your Regulatory needs in Singapore, fill out the contact form or write to us at sales@freyrsolutions.com.
